GleamWall
中文EN

VERA Vera Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1831828 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-64.8%
TTM EPS YoY-47.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-113.5%
ROA-84.5%
ROIC (approx.)-87.8%
Asset turnover—

Leverage & solvency

Liabilities / assets28.5%
Debt / equity0.23x
Current ratio7.91x
Interest coverage-57.40x

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.28M———$0———
Cost of revenue$3.30M———$0———
Gross profit$6.98M———$0———
R&D expense$41.25M$60.08M$86.01M$59.31M$56.47M$58.20M$41.28M$33.35M
SG&A expense$61.43M$52.41M$39.12M$34.90M$27.46M$21.95M$15.92M$15.57M
Operating income-$95.70M-$112.49M-$125.13M-$94.21M-$83.93M-$80.14M-$57.19M-$48.91M
Interest expense$1.87M$1.85M$1.82M$1.90M$1.96M$1.87M$1.79M$1.87M
Net income-$93.71M-$109.47M-$121.03M-$91.10M-$80.29M-$76.53M-$51.69M-$43.42M
EBITDA-$94.88M-$112.36M-$124.99M-$94.07M-$83.80M-$80.02M-$57.11M-$48.86M
EPS (basic)-1.30-1.52-1.69—-1.26-1.20-0.81—
EPS (diluted)-1.30-1.52-1.69—-1.26-1.20-0.81—
Weighted avg. shares (diluted)72.13M71.84M71.48M—63.85M63.79M63.67M—
Balance sheet
Cash & equivalents$55.32M$48.88M$114.35M$354.73M$57.77M$49.12M$55.09M$92.65M
Short-term investments$328.72M$450.29M$482.41M$359.86M$439.62M$507.71M$534.74M$548.21M
Receivables$11.98M——$0————
Inventory$7.08M——$0————
Current assets$441.29M$527.49M$615.80M$728.88M$511.31M$571.35M$606.08M$651.22M
PP&E, net—$813,000$945,000$1.37M$1.16M$1.15M$1.06M$960,000
Intangibles$20.50M——$0————
Total assets$465.75M$532.98M$621.74M$734.73M$517.50M$578.53M$610.17M$655.68M
Current liabilities$55.77M$48.32M$45.15M$53.45M$41.88M$33.55M$21.89M$25.37M
Long-term debt$75.43M$75.23M$75.03M$74.84M$74.65M$74.46M$50.91M$50.69M
Total debt$75.43M$75.23M$75.03M$74.84M$74.65M$74.46M$50.91M$50.69M
Total liabilities$132.57M$125.23M$122.04M$130.21M$118.62M$110.25M$75.17M$78.53M
Shareholders' equity$333.19M$407.76M$499.70M$604.52M$398.88M$468.28M$535.00M$577.15M
Net debt$20.11M$26.35M-$39.32M-$279.89M$16.88M$25.34M-$4.18M-$41.96M
Cash flow statement
Operating cash flow-$99.18M-$100.25M-$106.50M-$69.99M-$61.91M-$54.80M-$54.41M-$39.18M
Capital expenditure$0$0$23,000$102,000$133,000$208,000$187,000$645,000
Free cash flow-$99.18M-$100.25M-$106.52M-$70.10M-$62.04M-$55.01M-$54.59M-$39.83M
Investing cash flow$101.91M$32.86M-$137.82M$80.66M$69.76M$28.54M$15.32M-$221.38M
Financing cash flow$3.71M$1.92M$3.94M$286.28M$797,000$20.29M$1.53M$325.95M
Depreciation & amortization$823,000$132,000$140,000$135,000$129,000$119,000$85,000$55,000
Stock-based compensation$15.73M$15.86M$13.21M$10.96M$9.74M$9.47M$7.74M$6.22M
Share buybacks———$0———$0

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.